TALENT Study: Phase II Trial of Adjuvant L-TIL Plus Tislelizumab in Resectable NSCLC Without pCR After Neoadjuvant Chemoimmunotherapy

NCT07330037 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

41

Enrollment

OTHER

Sponsor class

Conditions

NSCLC

Interventions

BIOLOGICAL: L-TIL cells injection
DRUG: Tislelizumab

Sponsor

Tianjin Medical University Cancer Institute and Hospital